Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 3Phase 1 3Phase NA 1Phase 3 1

Status

Completed 20Terminated 16Active not recruiting 15Recruiting 13Unknown 6Withdrawn 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 32Carcinoma, Non-Small-Cell Lung 29Leukemia, Myeloid, Acute 27Melanoma 25Neoplasms 22Lymphoma 21Pancreatic Neoplasms 18Multiple Myeloma 18Recurrence 17Lung Neoplasms 17Leukemia 17Ovarian Neoplasms 16Neoplasm Metastasis 15Lymphoma, Non-Hodgkin 15Carcinoma, Hepatocellular 15Colorectal Neoplasms 14Lymphoma, Follicular 13Myelodysplastic Syndromes 12Lymphoma, B-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Prostatic Neoplasms 10Lymphoma, Mantle-Cell 10Brain Neoplasms 10Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Liver Neoplasms 9Glioma 9

Interventions

pembrolizumab 2yeast-CEA vaccine 1avelumab 1Radiosurgery 1Omacor 1Leucovorin 1Fulvestrant 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Bevacizumab 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Carcinoma, Transitional Cell × Clear all
NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

NCT05234606 2022-04-12

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Silverback Therapeutics

Phase 1/2 Withdrawn
BreastGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Triple Negative Breast Neoplasms

NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡